AHR INHIBITORS AND USES THEREOF
The present invention provides AHR inhibitors, formulations and unit dosage forms thereof, and methods of use thereof.
1 . A spray dried intermediate (SDI) formulation comprising compound A,
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable polymer.
2 . The SDI formulation of claim 1 , comprising compound A free base.
3 . The SDI formulation of claim 1 , comprising compound A hemi-maleate.
4 . The SDI formulation of any one of claims 1 - 3 , wherein the pharmaceutically acceptable polymer is selected from PVP-VA, HPMC, HPMCP-55, HPMCAS-M, TPGS, HPMCAS-L, and MCC.
5 . The SDI formulation of any one of claims 1 - 4 , comprising about 25-40% wt compound A, or a pharmaceutically acceptable salt thereof.
6 . The SDI formulation of any one of claims 1 - 5 , wherein the pharmaceutically acceptable polymer is about 60-75% wt.
7 . The SDI formulation of any one of claims 1 - 6 , comprising 40:60 (wt %) compound A free base:HPMCAS-M.
8 . A unit dosage form comprising the SDI formulation of any one of claims 1 - 7 .
9 . The unit dosage form of claim 8 , wherein the SDI formulation is about 55-65 wt % of the unit dosage form.
10 . The unit dosage form of claim 8 or 9 , which is an immediate release (IR) tablet.
11 . The unit dosage form of any one of claims 8 - 10 , further comprising a filler selected from mannitol and lactose.
12 . The unit dosage form of any one of claims 8 - 11 , further comprising a disintegrant Ac-Di-Sol.
13 . The unit dosage form of any one of claims 8 - 12 , further comprising a thickening agent Cab-O-Sil.
14 . The unit dosage form of any one of claims 8 - 13 , further comprising sodium stearyl fumarate.
15 . The unit dosage form of any one of claims 8 - 14 , further comprising a binder HPC Nisso SSL SFP.
16 . The unit dosage form of any one of claims 8 - 15 , which has a full release in about 3 minutes in a sink dissolution test.
17 . A method for treating cancer in a patient, comprising administering to the patient a therapeutically effect amount of the SDI formulation of any one of claims 1 - 7 , or the unit dosage form of any one of claims 8 - 16 .
18 . The method of claim 17 , wherein the cancer is selected from a hematological cancer, lymphoma, myeloma, leukemia, a neurological cancer, skin cancer, breast cancer, prostate cancer, colorectal cancer, lung cancer, head and neck cancer, gastrointestinal cancer, liver cancer, pancreatic cancer, genitourinary cancer, bone cancer, renal cancer, and vascular cancer.
19 . The method of claim 17 , wherein the cancer is selected from:
urothelial carcinoma, for example, bladder cancer or transitional cell carcinoma;
head and neck squamous cell carcinoma;
melanoma, for example, a uveal melanoma;
ovarian cancer, for example, a serous subtype of ovarian cancer;
renal cell carcinoma, for example, a clear cell renal cell carcinoma subtype;
cervical cancer;
gastrointestinal/stomach (GIST) cancer, for example, a stomach cancer;
non-small cell lung cancer (NSCLC), for example, advanced and/or metastatic NSCLC;
acute myeloid leukemia (AML); and
esophageal cancer.
20 . The method of any one of claims 17 - 19 , wherein the method comprises administering to the patient about 200-1600 mg (for example, about 200 mg, about 400 mg, about 600 mg, about 800 mg, about 1000 mg, about 1200 mg, or about 1600 mg) of compound A, or a pharmaceutically acceptable salt thereof, daily.
21 . Use of a therapeutically effect amount of the SDI formulation of any one of claims 1 - 7 , or the unit dosage form of any one of claims 8 - 16 , for treating cancer in a patient.
22 . The use of claim 21 , wherein the cancer is selected from a hematological cancer, lymphoma, myeloma, leukemia, a neurological cancer, skin cancer, breast cancer, prostate cancer, colorectal cancer, lung cancer, head and neck cancer, gastrointestinal cancer, liver cancer, pancreatic cancer, genitourinary cancer, bone cancer, renal cancer, and vascular cancer.
23 . The use of claim 21 , wherein the cancer is selected from:
urothelial carcinoma, for example, bladder cancer or transitional cell carcinoma;
head and neck squamous cell carcinoma;
melanoma, for example, a uveal melanoma;
ovarian cancer, for example, a serous subtype of ovarian cancer;
renal cell carcinoma, for example, a clear cell renal cell carcinoma subtype;
cervical cancer;
gastrointestinal/stomach (GIST) cancer, for example, a stomach cancer;
non-small cell lung cancer (NSCLC), for example, advanced and/or metastatic NSCLC;
acute myeloid leukemia (AML); and
esophageal cancer.
24 . The use of any one of claims 21 - 23 , wherein the SDI formulation or the unit dosage form comprises about 200-1600 mg (for example, about 200 mg, about 400 mg, about 600 mg, about 800 mg, about 1000 mg, about 1200 mg, or about 1600 mg) of compound A, or a pharmaceutically acceptable salt thereof, and is administered daily.